Hanall Biopharma Co., Ltd. (KRX: 009420)

Market Cap	2.01T
Revenue (ttm)	130.37B
Net Income (ttm)	-6.19B
Shares Out	50.71M
EPS (ttm)	-122.33
PE Ratio	n/a
Forward PE	92.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	532,752
Open	40,350
Previous Close	40,500
Day's Range	40,000 - 41,550
52-Week Range	28,500 - 52,000
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Hanall Biopharma

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascul...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 306
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 009420

Financial Performance

In 2023, Hanall Biopharma's revenue was 134.91 billion, an increase of 22.65% compared to the previous year's 110.00 billion. Earnings were 3.51 billion, an increase of 1295.23%.